UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
UvA-DARE (Digital Academic Repository)
Response monitoring during neoadjuvant targeted treatment in early stage non‐
small cell lung cancer
van Gool, M.H.
Publication date
2019
Document Version
Other version
License
Other
Link to publication
Citation for published version (APA):
van Gool, M. H. (2019). Response monitoring during neoadjuvant targeted treatment in early
stage non‐small cell lung cancer.
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
non-small cell lung cancer
RESPONS MONIT
ORING DURING NEO
AD JUV ANT T ARGETED TREA IN EARL Y ST AGE NON -SMALL CELL L UNG C ANCER
Response monitoring during neoadjuvant
targeted treatment in early stage
non‐small cell lung cancer
Copyright 2019 Matthijs van Gool All rights reserved. No part of this thesis may be reproduced or distributed in any form or by any means, without the prior written permission of the author or publisher. Cover: Detail of Victory Boogie Woogie (1942‐1944), Piet Mondriaan
Collection of Gemeente Museum, The Hague. State property of the Netherlands through the Stichting Nationaal Fonds Kunstbezit.
Printed with permission of Gemeente Museum, The Hague.
Response monitoring during neoadjuvant targeted treatment in early stage non‐small cell lung cancer
ACADEMISCH PROEFSCHRIFT ter verkrijging van de graad van doctor aan de Universiteit van Amsterdam op gezag van de Rector Magnificus mw. prof. dr. ir. K.I.J. Maex ten overstaan van een door het College voor Promoties ingestelde commissie, in het openbaar te verdedigen in de Agnietenkapel op vrijdag 25 oktober 2019, te 10.00 uur door Matthijs Hendrik van Gool geboren te Alkmaar
Copromotor: Mw. dr. H.M. Klomp NKI‐AvL
Overige leden: Prof. dr. J.T. Annema AMC‐UvA Prof. dr. J. Booij AMC‐UvA Dr. W.J.P. van Boven AMC‐UvA Prof. dr. J.A. van der Hage Universiteit Leiden Dr. A.G.M. Hoofwijk Zuyderland Medisch Centrum Prof. mr. dr. B.A.J.M. de Mol AMC‐UvA Faculteit der Geneeskunde
Table of contents
Chapter 1 General introduction and outline of the thesis. 7 Chapter 2 FDG‐PET/CT response evaluation during EGFR‐TKI treatment 19 in patients with NSCLC. World J Radiol. 2014 Jul 28;6(7):392‐8 Chapter 3 (18)F‐fluorodeoxyglucose positron emission tomography 33 versus computed tomography in predicting histopathological response to epidermal growth factor receptor‐tyrosine kinase inhibitor treatment in resectable non‐small cell lung cancer. Ann Surg Oncol. 2014 Sep;21(9):2831‐7 Chapter 4 Timing of metabolic response monitoring during erlotinib 47 treatment in non‐small cell lung cancer. J Nucl Med. 2014 May 8;55(7):1081‐6 Chapter 5 Tumor heterogeneity on 18F‐FDG‐PET/CT for response 65 monitoring in non‐small cell lung cancer treated with erlotinib. J Thorac Dis. 2016 Mar;8(3):E200‐3 Chapter 6 Skin rash in patients treated with neoadjuvant erlotinib 73 (Tarceva) in resectable non‐small cell lung cancer: Predictor for tumor response and survival? J Cancer Res Ther. 2017; 5(7):45‐49 Chapter 7 Prognostic value of pre‐operative glucose‐corrected 87 maximum standardized uptake value in patients with non‐small cell lung cancer after complete surgical resection and 5‐year follow‐up. Ann Nucl Med (2016) 30:362–8 Chapter 8 Neoadjuvant erlotinib in patients with operable non‐small 101 cell lung cancer: 5‐year follow‐up of an open‐label, phase II study. Submitted Chapter 9 General discussion and future perspectives 117List of publications 143 List of abbreviations 147 Dankwoord 151 Curriculum vitae 159
